Celldex Therapeutics, Inc. Cash and Restricted Cash
Celldex Therapeutics, Inc. (CLDX) had Cash and Restricted Cash of $47.45 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-06
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $47.45M.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $35.73M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $28.87M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $36.04M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents |
|---|---|
| 2026-06-30 | $47.45M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $35.73M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $28.87M 10-Q · filed 2026-08-06 |
| 2025-09-30 | $36.04M 10-Q · filed 2025-11-10 |
| 2025-06-30 | $23.04M 10-Q · filed 2026-08-06 |
| 2025-03-31 | $17.14M 10-Q · filed 2026-05-07 |
| 2024-12-31 | $28.36M 10-Q · filed 2026-08-06 |
| 2024-09-30 | $36.40M 10-Q · filed 2025-11-10 |
| 2024-06-30 | $42.74M 10-Q · filed 2025-08-07 |
| 2024-03-31 | $115.08M 10-Q · filed 2025-05-08 |
| 2023-12-31 | $34.81M 10-K · filed 2026-02-25 |
| 2023-09-30 | $21.13M 10-Q · filed 2024-11-06 |
| 2023-06-30 | $28.22M 10-Q · filed 2024-08-08 |
| 2023-03-31 | $54.12M 10-Q · filed 2024-05-06 |
| 2022-12-31 | $29.43M 10-K · filed 2026-02-25 |
| 2022-09-30 | $18.58M 10-Q · filed 2023-11-02 |
| 2022-06-30 | $28.40M 10-Q · filed 2023-08-08 |
| 2022-03-31 | $25.29M 10-Q · filed 2023-05-04 |
| 2021-12-31 | $39.14M 10-K · filed 2025-02-27 |
| 2021-09-30 | $72.18M 10-Q · filed 2022-11-09 |
| 2021-06-30 | $43.45M 10-Q · filed 2022-08-08 |
| 2021-03-31 | $69.31M 10-Q · filed 2022-05-05 |
| 2020-12-31 | $43.84M 10-K · filed 2024-02-26 |
| 2019-12-31 | $11.23M 10-K · filed 2023-02-28 |
| 2018-12-31 | $24.31M 10-K · filed 2022-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEOGEN CORP (NEOG) | United States | $2.979B | -247.49 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |